Latest news with #IGE
Business Wire
22-06-2025
- Business
- Business Wire
NPCE Investors Have Opportunity to Join NeuroPace, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of NeuroPace, Inc. ('NeuroPace' or 'the Company') (NASDAQ: NPCE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. NeuroPace issued a press release on May 27, 2025, "announcing the preliminary primary endpoint one-year results of the two-year NAUTILUS study evaluating safety and effectiveness of the RNS System for treatment of individuals with drug-resistant idiopathic generalized epilepsy (IGE)." According to the Company, "The study did not reach statistical significance for the primary effectiveness endpoint in the overall study population, which was to show a longer time to a second generalized tonic-clonic seizure in the active stimulation group compared to the sham stimulation group." Based on this news, shares of NeuroPace fell by almost 28.4% on May 27, 2025. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Yahoo
27-05-2025
- Business
- Yahoo
Why Is NeuroPace Stock Falling After Epilepsy Treatment Study Data?
NeuroPace, Inc. (NASDAQ:NPCE) released preliminary primary endpoint one-year results of the two-year NAUTILUS study evaluating safety and effectiveness of the RNS System for drug-resistant idiopathic generalized epilepsy (IGE). The study met its primary 12-week post-implant safety endpoint, demonstrating a low rate of serious adverse events related to the device and implant procedure. The study did not reach statistical significance for the primary effectiveness endpoint in the overall study population, which was to show a longer time to a second generalized tonic-clonic seizure in the active stimulation group compared to the sham stimulation the data did show a clinically meaningful and statistically significant response in the primary effectiveness endpoint within a subgroup of patients with lower baseline frequency of generalized tonic-clonic seizures, representing most trial participants. Additionally, the company said that within the entire trial population, clinically relevant data, including median percent seizure reduction, responder rates, and improvement in seizure-free days, showed numerically robust and clinically meaningful improvements over the first year of treatment and continued in those who have progressed to the second year. The company will engage with the FDA to discuss regulatory pathways based on the data. These discussions may include the possibility of utilizing the overall median seizure reduction data across the full study population and pursuing a more targeted indication focused on patients with lower baseline seizure frequency who may represent a majority of IGE patients. In April, NeuroPaces terminated its distribution relationship for SEEG products and will begin winding down the relationship in the fourth quarter of 2025 and continuing through the first quarter of 2026. NeuroPace announced three-year effectiveness data from the Post-Approval Study (PAS) of the RNS System in April. The data showed an 82% median reduction in seizures in adults treated with brain-responsive stimulation for drug-resistant focal epilepsy and seizure freedom, with 42% of patients remaining seizure-free for 6+ months. Sales grew 24% to $22.5 million in the first quarter of 2025. RNS System revenue grew 29%, excluding revenue from implants in the NAUTILUS study in the first quarter of 2024. Increased sales of the RNS System primarily drove the company's revenue growth. The company also continued to generate meaningful revenue from sales of SEEG products. NeuroPace raised the fiscal year 2025 sales guidance from $92 million-$96 million to $93 million-$97 million compared to the consensus of $93.64 million. Price Action: NPCE stock is down 33.90% at $11.68 at the last check Tuesday. Read Next:Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Why Is NeuroPace Stock Falling After Epilepsy Treatment Study Data? originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
